Absence of DNAM-1 ligands does not prolong skin allograft survival.
Abstract
(A) Skin grafts from fully MHC-mismatched WT BALB/c (n = 19) or CD155 KO (n = 24) donors were performed on B6 recipients. Median survival time: 9 vs. 10 days (WT vs. CD155 KO). (B) Skin grafts from WT BALB/c (n = 7) or CD155 KO (n = 8) donors were performed on minor antigen mismatched DBA/2 recipients. Median survival time: 13 vs. 15 days (WT vs. CD155 KO). (C) Skin grafts from fully MHC-mismatched WT B6 (n = 8) or CD112 KO (n = 8) donors were performed on CBA recipients. Median survival time: 11 vs. 12 days (WT vs. CD112 KO). (D) Skin grafts from MHC I antigen mismatched B6 (n = 7) or CD112 (n = 8) donors were performed on bm1 recipients. Median survival time: 25.5 vs. 21 days (WT vs. CD112 KO, P = 0.01). (TIF)</p- Image
- Figure
- Medicine
- Cell Biology
- Genetics
- Pharmacology
- Biotechnology
- Immunology
- Developmental Biology
- Marine Biology
- Cancer
- Hematology
- Biological Sciences not elsewhere classified
- ligands CD 112
- T Cell Costimulation
- CD 155
- CD 112
- Kidney Transplantation DNAX accessory protein
- mouse kidney transplantation model
- DNAM
- allospecific T cell response